Search results
68 results found
Polygenic scores for cancerReportAn overview of what is known about polygenic scores and what they could mean for cancer prediction, prevention and management. A short report for health policy makers and other stakeholders.
Are synthetic health data ‘personal data’?ReportCommissioned by the MHRA, we evaluated the current legal framework, regulatory guidance and latest legal commentary to assess whether—or in what circumstances—synthetic health data might be considered ‘personal data’
Evaluation of polygenic risk score applicationsReportHow current evidence is inadequate to determine clinical validity or utility of a polygenic score product in relation to its intended purpose and what is needed to resolve the gaps
Control of patient information in the COVID-19 eraReportThe ethical and legal considerations that need to be taken into account by policymakers should there be any future extension, or exception for COVID-19 purposes.
Implementing polygenic scores for cardiovascular disease into NHS Health ChecksReportWe evaluate the NHS Health Check programme as a possible exemplar for the introduction of the routine use of polygenic score analysis.
The ethical and legal framework for a Genomics England and Sano Genetics participant engagement platformReportA commissioned report for Genomics England
Polygenic scores and clinical utilityReportThis report brings together key concepts around clinical utility. Using our expertise on genetic test evaluation and regulation we consider how to better assess the potential utility of polygenic scores in healthcare.